For HCPs Only
Recent Clinical Updates
Loading latest clinical updates
All Authors
VP

HCP Connect Contributor

Dr. Vikram Patel

Dr. Vikram Patel contributes neurology drug update coverage for HCP Connect, with emphasis on source-verified therapeutic developments and practical clinical context for US-licensed practitioners. This profile links the author's recent clinical coverage, specialty focus, and professional contributor metadata in one place.

Recent Drug Updates

35 total

Neurology

FDA Approves Efgartigimod for Myasthenia Gravis: New Treatment Algorithm for AChR Negative MuSK Negative Patients

Efgartigimod approved for myasthenia gravis: new treatment algorithm for AChR negative MuSK negative patients.

May 14, 2026|3 min read|Via FDA

Neurology

FDA Extends PDUFA for Lecanemab Autoinjector: Weekly Home Administration for Alzheimer’s

FDA extends PDUFA for lecanemab: weekly home administration for Alzheimer’s disease treatment.

May 14, 2026|3 min read|Via FDA

Neurology

FDA Approves Efgartigimod for Myasthenia Gravis: New Treatment Algorithm for Seropositive and Seronegative Patients

Efgartigimod approved for myasthenia gravis: new treatment algorithm for seropositive and seronegative patients.

May 14, 2026|3 min read|Via FDA

Neurology

FDA Approves Lecanemab for Alzheimer: Coverage Criteria and MACE Monitoring

FDA approves lecanemab for Alzheimer: coverage criteria include amyloid PET scan and MACE monitoring.

May 12, 2026|3 min read|Via FDA

Neurology

FDA Approves Efgartigimod for Myasthenia Gravis: Treatment Algorithm for AChR Negative Patients

Efgartigimod approved for seronegative myasthenia gravis: new treatment algorithm for AChR negative patients.

May 12, 2026|3 min read|Via FDA

Neurology

FDA Approves Glatiramer Acetate Biosimilar for Relapsing MS: First Complex Injectable Generic

FDA approves glatiramer acetate biosimilar for relapsing MS, enhancing treatment access and affordability.

May 9, 2026|3 min read|Via FDA

Neurology

FDA Approves Donanemab for Alzheimer: Subcutaneous Dosing Options Available

FDA approves donanemab for Alzheimer: 27% cognitive decline reduction with new subcutaneous dosing option.

May 9, 2026|3 min read|Via FDA

Neurology

FDA Approves Lecanemab for Alzheimer: Biweekly IV vs Weekly SC Dosing

FDA approves lecanemab for Alzheimer: biweekly IV vs weekly SC dosing for better patient adherence.

May 9, 2026|3 min read|Via FDA

Neurology

FDA Approves Wellcovorin for Cerebral Folate Transport Deficiency: First-Ever Treatment

FDA approves Wellcovorin for cerebral folate transport deficiency, the first-ever treatment for this rare condition.

May 7, 2026|3 min read|Via FDA

Neurology

FDA Approves Ofatumumab and Natalizumab: High Efficacy Options for MS Management

FDA approves ofatumumab and natalizumab for MS: high-efficacy options reduce relapse rates and improve patient outcomes.

May 6, 2026|3 min read|Via FDA

Neurology

FDA Approves Lecanemab for Alzheimer: Patient Selection Criteria and Amyloid PET Eligibility

FDA approves lecanemab for Alzheimer: patient selection and amyloid PET eligibility criteria critical for treatment.

May 6, 2026|3 min read|Via WHO

Neurology

FDA Approves Donanemab for Alzheimer’s Disease: Amyloid Plaque Reduction in TRAILBLAZER-ALZ 2 Trial

FDA approves donanemab for Alzheimer’s disease: significant amyloid plaque reduction in TRAILBLAZER-ALZ 2 trial.

May 6, 2026|3 min read|Via FDA

Neurology

FDA Approves Wellcovorin for Cerebral Folate Transport Deficiency: First Treatment Available

FDA approves Wellcovorin for cerebral folate transport deficiency, the first treatment for this rare condition, improving patient outcomes.

May 4, 2026|3 min read|Via FDA

Neurology

FDA Approves Lecanemab for Alzheimer: Weekly Dosing to Enhance Treatment Adherence

FDA approves lecanemab for Alzheimer’s disease: 27% cognitive decline reduction with weekly dosing.

May 2, 2026|3 min read|Via FDA

Neurology

FDA Approves Ofatumumab and Natalizumab for High Efficacy in Multiple Sclerosis Treatment

FDA approves ofatumumab and natalizumab for multiple sclerosis: high-efficacy options for patients with relapsing forms.

Apr 30, 2026|3 min read|Via WHO

Neurology

FDA Approves Copper Histidinate for Menkes Disease: 78% Survival Benefit in Pediatric Patients

FDA approves Zycubo for Menkes disease: 78% survival benefit in pediatric patients.

Apr 30, 2026|3 min read|Via FDA

Gene Therapy

CRISPR Gene Therapy: A New Frontier in Sickle Cell Disease Treatment

Explore the latest advances in CRISPR gene therapy for sickle cell disease and its potential for curative treatment.

Apr 24, 2026|1 min read|Via NEJM

Neurology

Improve Parkinson's Symptoms with Targeted Therapy

Discover how optimized speech and movement therapy can improve motor and nonmotor symptoms in Parkinson's disease patients, enhancing overall quality of life.

Apr 22, 2026|2 min read|Via Neurology Live

Medical Devices

Streamline Molecular Testing with Integrated Solutions

Discover how a strategic partnership can simplify workflow and improve biospecimen storage for Contract Research Organizations and pharmaceutical partners.

Apr 17, 2026|2 min read|Via Medical Device News Magazine

Neurology

New Target to Reduce MS Inflammation

Discover how mesenchymal stem cells in secondary progressive multiple sclerosis drive proinflammatory T-cell activity and potential therapeutic targets to reduce inflammation in MS...

Apr 16, 2026|4 min read|Via Neurology Live

Neurology

Identify Macromastia to Reduce Headache Risk

Learn how recognizing macromastia in women can help reduce headache risk and improve patient outcomes with referral options and conservative treatments.

Apr 16, 2026|2 min read|Via Neurology Live

Medical Research

Reduce PPIX Accumulation by 30% with GlyT1 Inhibition

Discover how blocking extracellular glycine uptake mitigates protoporphyria, reducing protoporphyrin IX accumulation in erythrocytes and plasma tissues by inhibiting GlyT1.

Apr 12, 2026|7 min read|Via Journal of Clinical Investigation

Medical Research

Boost Transplant Success with Novel Immunosuppression

Discover how costimulation blockade promotes tolerance, reducing rejection in cardiac transplantation and improving patient outcomes with alternative therapies.

Apr 12, 2026|5 min read|Via Journal of Clinical Investigation

Medical Research

New Compound Induces Lytic Cell Death in Tumor Models

Discover how a novel compound triggers pyroptosis, offering a potential therapeutic approach to overcome melanoma's resistance to apoptosis and activate antitumoral immunity.

Apr 11, 2026|24 min read|Via Journal of Clinical Investigation

Medical Research

TBX3 Mutations Linked to Hepatic Clonal Expansion

Discover how somatic mutations in TBX3 impact liver disease, including hepatic clonal expansion and VLDL secretion, with implications for clinical practice.

Apr 11, 2026|39 min read|Via Journal of Clinical Investigation

Health News

Mental Health Screenings in Schools: What's at Stake for Patients

Experts weigh in on proposed changes to mental health screenings in schools, citing potential consequences for early intervention and treatment outcomes.

Apr 10, 2026|6 min read|Via NPR Health Shots

Medical Research

Long COVID's Impact on Menstrual Cycles

Research explores the bidirectional relationship between long COVID and menstruation, shedding light on menstrual disturbances in women with long-term COVID-19 symptoms.

Apr 9, 2026|58 min read|Via Nature Communications

Medical Research

Identify Aggressive Breast Cancer Sooner

New lymph node study reveals how breast cancer evades immune detection, informing treatment choices and survival chances for patients.

Apr 7, 2026|7 min read|Via Medical Xpress

Neurology

New Treatment Lowers Heart Attack and Stroke Risk

Learn about a new medication that can help reduce the risk of heart attack, stroke, and cardiovascular death in people with type 2 diabetes.

Apr 5, 2026|4 min read|Via Neurology Live

Medical Research

Unlock Tomatillo Benefits

Discover the taste and health benefits of tomatillos, a nutrient-rich food that's easy to add to your diet for a healthier you.

Apr 3, 2026|4 min read|Via Medical Xpress

Wellness

Identify Hidden Heart Attack Signs

Learn to distinguish between heartburn and potential heart attack symptoms to improve patient outcomes and save lives.

Apr 1, 2026|4 min read|Via Sound Health Lasting Wealth

Neurology

Empower Your Neurology Career

Learn how to overcome challenges and advance your neurology career with expert-led sessions and networking opportunities at the Women in Neurology Conference.

Mar 29, 2026|5 min read|Via Neurology Live

Neurology

Empower Your Neurology Career with Community Support

Connect with fellow women neurologists, enhance your skills, and relax at a weekend conference designed for professional and personal growth.

Mar 29, 2026|6 min read|Via Neurology Live

Neurology

Reduce Dyskinesia with Continuous Infusion Therapy

Discover how continuous infusion therapies can provide stable symptom control and reduce "off" time for Parkinson's disease patients experiencing motor fluctuations.

Mar 29, 2026|2 min read|Via Neurology Live

Digital Health

AI Automates 30% of Patient Calls

Discover how conversational AI can reduce administrative burdens and improve patient experience, freeing up more time for healthcare professionals to focus on care.

Mar 28, 2026|2 min read|Via HIT Consultant
Dr. Vikram Patel | HCP Connect Authors | HCP Connect